SCTL

Societal CDMO, Inc.

0.37 USD

Last updated Dec 2, 22:28 UTC

Yesterday HIGH

$0.38

Yesterday LOW

$0.36

52w HIGH

$1.86

52w LOW

$0.26

EPS

-0.05

PE

-7.47

Next Earnings

Feb 28, 2024

Overview News Government Trades

Societal CDMO, Inc. stock is up 6.77% since 30 days ago. The next earnings date is Feb 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 4 December’s closed higher than November. 100% of analysts rate it a buy.

Recro Pharma, Inc. is a pharmaceutical company, whcih is focused on products for hospitals and ambulatory care settings. The company is developing non-opioid products for treatment of serious acute pain. It offers drug solutions for cancer, musculoskeletal disorders and peripheral neuropathy, cancer breakthrough and acute post-operative pain. The company's products include Dex-INR and Fadolmidine, which is under development. Recro Pharma was founded by Geraldine A. Henwood on November 15, 2007 and is headquartered in Malvern, PA.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

Malvern, United States Of America

Website

www.recropharma.com

Lara Goldstein

Mon Aug 21, 2023

Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports

Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds
Lara Goldstein

Wed Aug 16, 2023

$21.8M Revenue For NASDAQ-Listed Psychedelics Ancillary Company Societal CDMO's Q2 2023

Societal CDMO Inc. (NASDAQ: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for small molecule therapeutics, reported financial results for the three and six months ended June 30, 2023.
richadhand@benzinga.com

Tue Aug 15, 2023

RBC Capital Reiterates Outperform on Societal CDMO, Maintains $2 Price Target

RBC Capital analyst Sean Dodge reiterates Societal CDMO (NASDAQ:SCTL) with a Outperform and maintains $2 price target.
richadhand@benzinga.com

Tue Aug 15, 2023

Stephens & Co. Reiterates Overweight on Societal CDMO, Maintains $2.5 Price Target

Stephens & Co. analyst Jacob Johnson reiterates Societal CDMO (NASDAQ:SCTL) with a Overweight and maintains $2.5 price target.
Happy Mohamed

Mon Aug 14, 2023

Societal CDMO Revises FY23 EBITDA Guidance To $12M-$15M From $15M-$18M

"The second quarter was a highly productive period. During the quarter, we continued to aggressively pursue and win new business, as well as expand multiple programs with existing customers.
Benzinga Newsdesk

Mon Aug 14, 2023

Societal CDMO Q2 EPS $(0.04) Misses $(0.03) Estimate, Sales $21.80M Miss $21.94M Estimate

Societal CDMO (NASDAQ:SCTL) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.03) by 33.33 percent. This is a 33.33 percent increase over losses of $(0.06) per share from
Benzinga Insights

Mon Aug 14, 2023

Earnings Scheduled For August 14, 2023

Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million.
Benzinga Insights

Fri Aug 11, 2023

A Preview Of Societal CDMO's Earnings
Benzinga Insights

Wed Aug 9, 2023

Earnings Scheduled For August 9, 2023

Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is estimated to report quarterly earnings at $0.96 per share on revenue of $18.11 billion.
Benzinga Insights

Tue Aug 8, 2023

Societal CDMO's Earnings Outlook